LDN®
IMMUNOASSAYS AND SERVICES
BIOGENIC AMINES & NEUROSCIENCE | ENDOCRINOLOGY | FOOD SAFETY
LABOR DIAGNOSTIKA NORD GmbH & Co. KG | Am Eichenhain 1 | 48531 Nordhorn | Germany | Tel. +49 5921 8197-0 | Fax +49 5921 8197-222 | info@ldn.de | www.ldn.de

Instructions for use

Reverse T3 (rT3) ELISA

REF TF E-2500

Reverse T3 (rT3) ELISA

INTENDED USE

For the direct quantitative determination of Reverse Triiodothyronine (rT3) in human serum and plasma by an enzyme immunoassay.

PRINCIPLE OF THE TEST

The rT3 ELISA is a competitive enzyme immunoassay, where the antigen (rT3 present in standards, controls and patient samples) competes with a biotin-labelled antigen (rT3-Biotin conjugate) for a limited quantity of antibody which is coated on the microplate wells. After one hour incubation followed by the first washing, unbound materials are removed and a Streptavidin-HRP conjugate is added and incubated for 30 minutes. Following a second washing, the TMB substrate is added. The enzymatic reaction is terminated by addition of the stopping solution, upon which the color intensity is measured with a microplate reader. The color intensity is inversely proportional to the concentration of rT3 in the sample. The set of kit standards that are run simultaneously with the samples is used to plot a standard curve and determine the concentration of rT3 in samples and controls.

CLINICAL APPLICATIONS

3,3′,5′-Triiodo-L-thyronine also known as reverse triiodothyronine or reverse T3 (rT3), differs from 3,3′,5-Triiodo-L-thyronine (T3) in the positions of the iodine atoms in the molecule. The majority of circulatory rT3 is synthesized by peripheral deiodination of thyroxine (T4).

Both T3 and rT3 bind to thyroid hormone receptors, but in contrast to T3, rT3 has not been found yet to stimulate receptor metabolic activity; it blocks receptor sites from T3 activation. The ratio of rT3 to T3 is a valuable biomarker of the metabolism and function of thyroid hormones because the process of 5′ monodeiodination that converts T4 to T3 and rT3 to 3,3′-T2 is inhibited in a number of non-thyroidal conditions such as fasting, anorexia nervosa, malnutrition, diabetes mellitus, stress, severe trauma or infection, hemorrhagic shock, hepatic dysfunction, pulmonary diseases and others. This scenario is known as "Sick euthyroid" syndrome or "Low T3" syndrome.

An elevated ratio of rT3 over T3 is therefore indicative of "sick euthyroid" syndrome and helps to exclude a diagnosis of hypothyroidism, particularly in critically ill patients 1–9.

The concentration of rT3 could be high in patients on the following medications: amiodarone, dexamethasone, propylthiouracil, ipodate, propranolol, and the anesthetic halothane. The concentration of rT3 could be low in patients on Dilantin, which decreases rT3 due to its displacement from thyroxine- binding globulin and therefore generates an excessive clearance of rT3.

PROCEDURAL CAUTIONS AND WARNINGS

1. This kit is intended for in vitro use only.
2. Practice good laboratory practices when handling kit reagents and specimens. This includes:
   - Do not pipette by mouth.
   - Do not smoke, drink, or eat in areas where specimens or kit reagents are handled.
   - Wear protective clothing and disposable gloves.
   - Wash hands thoroughly after performing the test.
   - Avoid contact with eyes; use safety glasses; in case of contact with eyes, flush eyes with water immediately and contact a doctor.
3. Users should have a thorough understanding of this protocol for the successful use of this kit. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
4. Avoid microbial contamination of reagents.
5. A standard curve must be established for every run.
6. It is recommended to all customers to prepare their own control materials or serum pools which should be included in every run at a high and low level for assessing the reliability of results.
7. The controls (included in kit) must be included in every run and their results must fall within the ranges stated in the quality control certificate; a failed control result might indicate improper procedural techniques or pipetting, incomplete washing or inadequate reagent storage.
8. When the use of water is specified for dilution or reconstitution, use deionized or distilled water.
9. All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of specimens.
10. Improper procedural techniques, imprecise pipetting, incomplete washing as well as improper reagent storage may be indicated when assay values for the control do not reflect established ranges.
11. When reading the microplate, the presence of bubbles in the wells will affect the optical densities (ODs). Carefully remove any bubbles before performing the reading step.
12. The substrate solution (TMB) is sensitive to light and should remain colourless if properly stored. Instability or contamination may be indicated by the development of a blue colour, in which case it should not be used.
13. The Biotin-rT3 conjugate solution is sensitive to light and should be of a light yellow color if stored properly; do not use if the solution appears dark green or black in color.

14. When dispensing the substrate and stopping solutions, do not use pipettes in which these liquids will come into contact with any metal parts.
15. To prevent contamination of reagents, use a new disposable pipette tip for dispensing each reagent, sample, standard and control.
16. Do not use kit components from different kit lots within a test and do not use any component beyond the expiration date printed on the label.
17. Kit reagents must be regarded as hazardous waste and disposed of according to local and/or national regulations.

LIMITATIONS

1. All the reagents within the kit are calibrated for the direct determination of rT3 in human serum and plasma. The kit is not calibrated for the determination of rT3 in other specimens of human or animal origin.
2. Do not use grossly haemolysed, lipemic, icteric or improperly stored serum or plasma samples.
3. Samples or control sera containing azide or thimerosal are incompatible with this kit and will lead to false results.
4. Do not use the results of this kit as the sole basis for a clinical diagnosis. For example, medications and heterophilic antibodies (in patients exposed to animals or animal products) can interfere with immunoassays. Consequently, the clinical diagnosis should include all aspects of patients background including the frequency of exposure to animals/ products and medications.

SAFETY CAUTIONS AND WARNINGS
POTENTIAL BIOHAZARDOUS MATERIAL

Human serum that may be used in the preparation of the standards and controls has been tested and found to be non-reactive for Hepatitis B surface antigen and has also been tested for the presence of antibodies to HCV and Human Immunodeficiency Virus (HIV) and found to be negative. No test method however, can offer complete assurance that HIV, HCV and Hepatitis B virus or any other infectious agents are absent. The reagents should be considered a potential biohazard and handled with the same precautions applied to blood specimens.
All human specimens should be considered a potential bio- hazard and handled as if capable of transmitting infections and in accordance with good laboratory practices.

CHEMICAL HAZARDS

Avoid contact with reagents containing TMB, hydrogen peroxide and sulfuric acid. If contacted with any of these reagents, wash with plenty of water. TMB is a suspected carcinogen.

SPECIMEN COLLECTION AND STORAGE

Serum:
Approximately 0.2 ml of serum is required per duplicate determination. Collect 4–5 ml of blood into an appropriately labelled tube and allow it to clot. Centrifuge and carefully remove the serum layer.

Plasma:
Approximately 0.2 ml of plasma is required per duplicate determination. Collect 4–5 ml of blood into EDTA plasma tubes. Centrifuge and carefully remove the plasma layer.

⚠ **Do not test samples the same day of the blood draw. The serum or plasma specimen samples must be stored at the recommended storage conditions for <u>at least 20 hours</u> prior to being tested.**

Upon serum or plasma collection, the samples must be stored:

a) Refrigerated (2–8°C) for a period of no longer than 5 days, or
b) Frozen (≤ -20°C) for a period of no longer than 3 months.
   Avoid multiple freeze/thaw cycles.

Consider all human specimens as possible biohazardous materials and take precautions when handling.

REAGENTS AND EQUIPMENT NEEDED BUT NOT PROVIDED

1. Precision pipette to dispense 25, 50, 100, 150 and 350 µl
2. Disposable pipette tips
3. Distilled or deionized water
4. Microplate shaker
   Recommendation: Orbital (3 mm diameter) set to 600 rpm
   Note: Other shakers may be used, provided the test results obtained with those shakers can meet the kit QC certificate criteria and the criteria of any end-user controls.
5. Microplate reader with a filter set at 450 nm and an upper OD limit of 3.0 or greater
6. Microplate washer (recommended)

REAGENTS PROVIDED

1. AA E-0030 WASH-CONC 10x **Wash Buffer Concentrate –** Requires Preparation **X10**

Contents: One bottle containing buffer with a non-ionic detergent and a non-mercury preservative.

Volume: 50 ml/bottle

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months or as indicated on label.

Preparation: Dilute the Wash Buffer concentrate 1:10 in distilled or deionized water to prepare the working wash buffer. If one whole plate is to be used dilute 50 ml of the wash buffer concentrate in 450 ml of water.

2. AA E-0055 SUBSTRATE **TMB Substrate** - Ready To Use.

Contents: One bottle containing tetramethylbenzidine and hydrogen peroxide in buffer.

Volume: 16 ml/bottle

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months or as indicated on label.

3. AA E-0080 STOP-SOLN **Stopping Solution** - Ready To Use.

Contents: One bottle containing 1M sulfuric acid.

Volume: 6 ml/bottle

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months or as indicated on label.

Hazards identification:

H315 Causes skin irritation.
H319 Causes serious eye irritation.

4. Standards and **Controls**- Ready To Use.

Cat. no.	Symbol	Standard	Concentration*	Volume/Vial
TF E-2501	STANDARD A	**Standard A**	0 ng/ml	1 ml
TF E-2502	STANDARD B	**Standard B**	0.02 ng/ml	1 ml
TF E-2503	STANDARD C	**Standard C**	0.1 ng/ml	1 ml
TF E-2504	STANDARD D	**Standard D**	0.4 ng/ml	1 ml
TF E-2505	STANDARD E	**Standard E**	1 ng/ml	1 ml
TF E-2506	STANDARD F	**Standard F**	2 ng/ml	1 ml
TF E-2551	CONTROL 1	**Control 1**	Refer to vial labels for acceptable range!	1 ml
TF E-2552	CONTROL 2	**Control 2**		1 ml

*Approximate value — please refer to vial labels for exact concentrations

Contents: rT3 in a protein-based buffer with a non-mercury preservative. Prepared by spiking buffer with rT3 to the concentrations in labels/QC certificate.

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months in unopened vials or as indicated on label.

5. TF E-2531 96 **Anti-Reverse T3 Polyclonal Antibody-Coated Break-Apart Well Microplate** - Ready To Use.

Contents: One 96 well (12x8) polyclonal antibody-coated microplate in a resealable pouch with desiccant.

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months or as indicated on label.

6. TF E-2510 BIOTIN-AB **Reverse T3-Biotin Conjugate** - Ready To Use.

Contents: Reverse T3-Biotin conjugate in a protein-based buffer with a non-mercury preservative.

Volume: 13 ml/bottle

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months or as indicated on label.

7. TF E-2540 CONJUGATE **Streptavidin - Horse Radish Peroxidase (HRP) Conjugate** - Ready To Use.

Contents: Streptavidin-HRP conjugate in a protein-based buffer with a non-mercury preservative.

Volume: 20 ml/bottle

Storage: Refrigerate at 2 - 8 °C

Stability: 12 months in unopened vial or as indicated on label.

ASSAY PROCEDURE

Specimen Pretreatment: Refer to **SPECIMEN COLLECTION AND STORAGE** section.

All reagents must reach room temperature before use. Standards, controls and specimen samples should be assayed in duplicate. Once the procedure has been started, all steps should be completed without interruption.

1.	After all kit components have reached room temperature, mix gently by inversion. Prepare the working wash buffer (see wash buffer concentrate under the section **REAGENTS PROVIDED**).
2.	Remove the required number of strips from the microplate and assemble into a plate frame. Reseal the bag and return any unused strips to the refrigerator.
3.	Pipette **25 µl of each standard, control and specimen sample** (serum or plasma) into correspondingly labelled wells in duplicate.
4.	Pipette **100 µl of the Reverse T3-Biotin conjugate** into each well. *(The use of a multichannel pipette is recommended.)*
5.	**Incubate** the microplate on a microplate shaker** **for 1 hour at room temperature.**
6.	**Wash** the wells with **350 µl/well of working wash buffer solution <u>3 times</u>**. After washings tap the plate firmly against absorbent paper to remove any residual liquid. *The use of an automatic strip washer is strongly recommended.* ***The accuracy of this assay depends on the correct execution of the washing procedure.***
7.	Pipette **150 µl of the Streptavidin-HRP conjugate** into each well. *(The use of a multichannel pipette is recommended.)*
8.	**Incubate** the microplate on a microplate shaker** **for 30 minutes at room temperature**.
9.	**Wash the wells <u>3 times</u>** using the same procedure as stated in step 6.
10.	Pipette **150 µl of the TMB substrate** into each well at timed intervals. *(The use of a multichannel pipette is recommended.)*
11.	Incubate the microplate on a microplate shaker** **for 10-20 minutes at room temperature** or until Standard A attains dark blue colour for desired OD.
12.	Pipette **50 µl** of **Stopping Solution** into each well at the same timed intervals as in step 10 *(the use of a multichannel pipette is recommended).* **Gently shake** the microplate by hand for ten seconds to ensure complete mixing of the stopping solution in the wells.
13.	**Measure** the absorbance **at 450 nm** with a microplate reader, **within 20 minutes** after addition of the stopping solution.
	** *See* **REAGENTS AND EQUIPMENT NEEDED BUT NOT PROVIDED** *(#4).*

CALCULATIONS

1. Calculate the mean optical density of each standard, control and specimen sample duplicate.
2. Use a 4-parameter or 5-parameter curve with immunoassay software to generate the control and sample concentration results or draw a standard curve on semi-log paper with the mean optical densities on the Y-axis and the standard concentration on the X-axis and read the concentration of controls and samples off the standard curve.
3. If a sample reads greater than 2 ng/ml then dilute it with Standard A at a dilution of no more than 1:5. The result obtained must be multiplied by the dilution factor.
4. To convert from ng/ml to ng/dl multiply the result by 100; to convert to nmol/l multiply the ng/dl result by 0.01536 or the ng/ml result by 1.536.

TYPICAL TABULATED DATA
Sample data only. **Do not** use to calculate results.

Standard	rT3 (ng/ml)	Mean OD (450 nm)
A	0	2.527
B	0.02	2.232
C	0.1	1.563
D	0.4	0.785
E	1	0.431
F	2	0.270
Unknown	0.15	1.289

TYPICAL STANDARD CURVE



PERFORMANCE CHARACTERISTICS

SENSITIVITY
The limit of detection (LoD) was determined from the analysis of at least 60 samples of the blank and a low value sample in two independent experiments and it was calculated as follows:
LoD = μB + 1.645σB + 1.645σS, where σB and σS are the standard deviation of the blank and low value sample and μB is the mean value of the blank.
The Limit of Detection (LoD) was determined to be **0.014 ng/ml.**

SPECIFICITY (CROSS REACTIVITY)
The following compounds were tested for cross-reactivity with rT3 cross-reacting at 100%:

Steroid	% Cross Reactivity
rT3	100
T3	0
T4	< 0.1
T2	0

INTERFERENT SUBSTANCES
The following substances did not show significant interference with the assay: haemoglobin up to 2 g/l, free and conjugated bilirubin up to 200 mg/l, triglycerides up to 5.0 mg/ml and Biotin up to 2.4 μg/ml.

PRECISION
The experimental protocol used a nested components-of-variance design with 2 testing days, two lots and five scientists per day, each scientist ran 2 tests (one test with each lot) per day, and two replicate measurements per run (a 2 x 5 x 2 x 2 design) for each sample. The results were analyzed with a two-way nested ANOVA and summarized in the table below.

Sample	Mean (ng/ml)	Within Run SD	Within Run CV (%)	Total SD	Total CV (%)
1	0.233	0.01	3.6	0.02	7.0
2	0.535	0.01	2.4	0.05	9.5
3	1.174	0.06	4.9	0.13	10.7
4	0.102	0.01	6.0	0.01	10.4
5	0.082	0.00	5.8	0.01	8.7
6	0.094	0.01	8.1	0.01	11.5
7	0.257	0.01	4.3	0.02	9.7
8	0.480	0.02	4.2	0.04	9.2

LINEARITY

The linearity study was performed with four human serum samples covering the range of the assay and following CLSI guideline EP6-A. The samples were diluted in Standard A up to a 1:5 dilution, tested in duplicate, and the results compared to the predicted concentration. The statistical analysis shows that the assay is sufficiently linear.



COMPARATIVE STUDIES

The rT3 ELISA kit (y) was tested manually, as well as with automated technology. The comparison of 40 samples yielded the following linear regression results:
y = 0.8452x + 0.0195, r = 0.96

REFERENCES VALUES

References values were obtained from commercial human specimens and calculated using a non-parametric method. Each laboratory must establish the range of reference values for their own population.

Group	N	Median (ng/ml)	95 % Range (ng/ml)	Total Range (ng/ml)
Serum	120	0.15	0.098 - 0.218	0.069 - 0.262
Plasma	120	0.15	0.098 - 0.26	0.072 - 0.309

REFERENCES

1. van den Beld AW, et al. Thyroid Hormone Concentrations, Disease, Physical Function and Mortality in Elderly Men. J Clin Endocrinol Metab. 2005; 90(1):6403 –9.
2. Holtorf K. Thyroid Hormone Transport into Cellular Tissue. Journal of Restorative Medicine. 2014; 3(1):53–68.
3. Holtorf K Peripheral Thyroid Hormone Conversion and Its Impact on TSH and Metabolioc Activity. Journal of Restorative Medicine. 2014; 3(1):30 –52.
4. Senese R et al. Thyroid: Biological Actions of "Non-classical" Thyroid Hormones. J Endocrinol. 2014; 221(2):R1–12.
5. Warner MH, Beckett GJ. Mechanisms Behind the Non- thyroidal Illness Syndrome: An Update. J Endocrinol. 2010; 205(1):1–13.
6. Peeters RP, et al. Tissue Thyroid Hormone Levels in Critical Illness. J Clin Endocrinol Metab. 2005; 90(12):6498–507.
7. Friberg L, et al. Association Between Increased Levels of Reverse Triiodothyronine and Mortality after Acute Myocardial Infarction. Am J Med. 2001; 111(9):699–703.
8. Pimentel, CR et al. Reverse T3 as a Parameter of Myocardial Function Impairment in Heart Failure. Int J Cardiol. 2010; 145(1):52–3.
9. Economidou F, et al. Thyroid Function During Critical Illness. Hormones (Athens). 2011; 10(2):117–24.
10 Thyroid Hormone Transport. National Academy of Hypothyroidism. https://www.nahypothyroidism.org/thyroid- hormone-transport/#reverseT3

CHANGE HISTORY

Previous Version:	6.0	**New Version:**	6.0a
Changes:	***REAGENTS PROVIDED*** Hazard labelling for component AA E-0080 updated		

Symbols:

	Storage temperature		Manufacturer		Contains sufficient for <n> tests
	Use-by date	LOT	Batch code	IVD	For in-vitro diagnostic use only!
	Consult instructions for use	CONT	Content		CE marking of conformity
	Caution	REF	Catalogue number		Distributor
	Date of manufacture				